Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Research Report 2026

1 Anti-VEGF Drugs for the Treatment of Wet AMD Market Overview
1.1 Product Definition
1.2 Anti-VEGF Drugs for the Treatment of Wet AMD by Type
1.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value by Type: 2025 vs 2032
1.2.2 Single target Drugs
1.2.3 Multi-target Drugs
1.3 Anti-VEGF Drugs for the Treatment of Wet AMD by Application
1.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue 2021–2032
1.4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales 2021–2032
1.4.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Anti-VEGF Drugs for the Treatment of Wet AMD Market Competition by Manufacturers
2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Manufacturers (2021–2026)
2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Anti-VEGF Drugs for the Treatment of Wet AMD, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Anti-VEGF Drugs for the Treatment of Wet AMD, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Anti-VEGF Drugs for the Treatment of Wet AMD, Product Types and Applications
2.7 Global Key Manufacturers of Anti-VEGF Drugs for the Treatment of Wet AMD, Date of Entry into the Industry
2.8 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Competitive Situation and Trends
2.8.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Anti-VEGF Drugs for the Treatment of Wet AMD Players Market Share by Revenue
2.8.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Scenario by Region
3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2021–2032
3.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2021–2026
3.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2027–2032
3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region: 2021–2032
3.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region: 2021–2026
3.3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region: 2027–2032
3.4 North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021–2032)
3.4.3 North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021–2032)
3.5.3 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Facts & Figures by Region
3.6.1 Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2021–2032)
3.6.3 Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021–2032)
3.7.3 Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021–2032)
3.8.3 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021–2032)
4.1.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021–2026)
4.1.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2027–2032)
4.1.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2021–2032)
4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021–2032)
4.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021–2026)
4.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2027–2032)
4.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2021–2032)
4.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type (2021–2032)
5 Segment by Application
5.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021–2032)
5.1.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021–2026)
5.1.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2027–2032)
5.1.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2021–2032)
5.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021–2032)
5.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021–2026)
5.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2027–2032)
5.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2021–2032)
5.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Coherus BioSciences
6.3.1 Coherus BioSciences Company Information
6.3.2 Coherus BioSciences Description and Business Overview
6.3.3 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
6.3.5 Coherus BioSciences Recent Developments/Updates
6.4 Regeneron Pharmaceuticals
6.4.1 Regeneron Pharmaceuticals Company Information
6.4.2 Regeneron Pharmaceuticals Description and Business Overview
6.4.3 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
6.4.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.5 Samsung Bioepis
6.5.1 Samsung Bioepis Company Information
6.5.2 Samsung Bioepis Description and Business Overview
6.5.3 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
6.5.5 Samsung Bioepis Recent Developments/Updates
6.6 Biocon Biologics
6.6.1 Biocon Biologics Company Information
6.6.2 Biocon Biologics Description and Business Overview
6.6.3 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
6.6.5 Biocon Biologics Recent Developments/Updates
6.7 Chengdu Kanghong Pharmaceutical
6.7.1 Chengdu Kanghong Pharmaceutical Company Information
6.7.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.7.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
6.7.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Chain Analysis
7.2 Anti-VEGF Drugs for the Treatment of Wet AMD Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Drugs for the Treatment of Wet AMD Production Mode & Process Analysis
7.4 Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Marketing
7.4.1 Anti-VEGF Drugs for the Treatment of Wet AMD Sales Channels
7.4.2 Anti-VEGF Drugs for the Treatment of Wet AMD Distributors
7.5 Anti-VEGF Drugs for the Treatment of Wet AMD Customer Analysis
8 Anti-VEGF Drugs for the Treatment of Wet AMD Market Dynamics
8.1 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Trends
8.2 Anti-VEGF Drugs for the Treatment of Wet AMD Market Drivers
8.3 Anti-VEGF Drugs for the Treatment of Wet AMD Market Challenges
8.4 Anti-VEGF Drugs for the Treatment of Wet AMD Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Competitive Situation by Manufacturers in 2025
Table 4. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Anti-VEGF Drugs for the Treatment of Wet AMD Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Anti-VEGF Drugs for the Treatment of Wet AMD, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Anti-VEGF Drugs for the Treatment of Wet AMD, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Anti-VEGF Drugs for the Treatment of Wet AMD, Product Types and Applications
Table 12. Global Key Manufacturers of Anti-VEGF Drugs for the Treatment of Wet AMD, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGF Drugs for the Treatment of Wet AMD Companies by Tier (Tier 1, Tier 2, Tier 3), based on Anti-VEGF Drugs for the Treatment of Wet AMD Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (K Dose), 2021–2026
Table 18. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region (2021–2026)
Table 19. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (K Dose), 2027–2032
Table 20. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region (2027–2032)
Table 21. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (US$ Million), 2021–2026
Table 22. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region (2021–2026)
Table 23. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (US$ Million), 2027–2032
Table 24. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region (2027–2032)
Table 25. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (K Dose), 2021–2026
Table 27. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (K Dose), 2027–2032
Table 28. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (US$ Million), 2021–2026
Table 29. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (K Dose), 2021–2026
Table 32. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (K Dose), 2027–2032
Table 33. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (K Dose), 2021–2026
Table 42. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (K Dose), 2027–2032
Table 43. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Country (US$ Million), 2027–2032
Table 50. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose) by Type (2021–2026)
Table 51. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose) by Type (2027–2032)
Table 52. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2021–2026)
Table 53. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2027–2032)
Table 54. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2021–2026)
Table 57. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2027–2032)
Table 58. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price (US$/Dose) by Type (2021–2026)
Table 59. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price (US$/Dose) by Type (2027–2032)
Table 60. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose) by Application (2021–2026)
Table 61. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose) by Application (2027–2032)
Table 62. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2021–2026)
Table 63. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2027–2032)
Table 64. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2021–2026)
Table 67. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2027–2032)
Table 68. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price (US$/Dose) by Application (2021–2026)
Table 69. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price (US$/Dose) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product
Table 79. Novartis Recent Developments/Updates
Table 80. Coherus BioSciences Company Information
Table 81. Coherus BioSciences Description and Business Overview
Table 82. Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product
Table 84. Coherus BioSciences Recent Developments/Updates
Table 85. Regeneron Pharmaceuticals Company Information
Table 86. Regeneron Pharmaceuticals Description and Business Overview
Table 87. Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product
Table 89. Regeneron Pharmaceuticals Recent Developments/Updates
Table 90. Samsung Bioepis Company Information
Table 91. Samsung Bioepis Description and Business Overview
Table 92. Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product
Table 94. Samsung Bioepis Recent Developments/Updates
Table 95. Biocon Biologics Company Information
Table 96. Biocon Biologics Description and Business Overview
Table 97. Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product
Table 99. Biocon Biologics Recent Developments/Updates
Table 100. Chengdu Kanghong Pharmaceutical Company Information
Table 101. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 102. Chengdu Kanghong Pharmaceutical Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Chengdu Kanghong Pharmaceutical Anti-VEGF Drugs for the Treatment of Wet AMD Product
Table 104. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Anti-VEGF Drugs for the Treatment of Wet AMD Distributors List
Table 108. Anti-VEGF Drugs for the Treatment of Wet AMD Customers List
Table 109. Anti-VEGF Drugs for the Treatment of Wet AMD Market Trends
Table 110. Anti-VEGF Drugs for the Treatment of Wet AMD Market Drivers
Table 111. Anti-VEGF Drugs for the Treatment of Wet AMD Market Challenges
Table 112. Anti-VEGF Drugs for the Treatment of Wet AMD Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 116. Authors List of This Report


List of Figures
Figure 1. Product Picture of Anti-VEGF Drugs for the Treatment of Wet AMD
Figure 2. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Type: 2025 & 2032
Figure 4. Single target Drugs Product Picture
Figure 5. Multi-target Drugs Product Picture
Figure 6. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Retail Pharmacies
Figure 10. Other
Figure 11. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size (US$ Million), 2021–2032
Figure 13. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Dose), 2021–2032
Figure 14. Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price (US$/Dose), 2021–2032
Figure 15. Anti-VEGF Drugs for the Treatment of Wet AMD Report Years Considered
Figure 16. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Manufacturers in 2025
Figure 17. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Anti-VEGF Drugs for the Treatment of Wet AMD Players: Market Share by Revenue in Anti-VEGF Drugs for the Treatment of Wet AMD in 2025
Figure 19. Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021–2032)
Figure 22. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Country (2021–2032)
Figure 23. United States Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021–2032)
Figure 26. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Country (2021–2032)
Figure 27. Germany Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region (2021–2032)
Figure 34. China Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021–2032)
Figure 42. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Anti-VEGF Drugs for the Treatment of Wet AMD by Type (2021–2032)
Figure 53. Global Revenue Market Share of Anti-VEGF Drugs for the Treatment of Wet AMD by Type (2021–2032)
Figure 54. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price (US$/Dose) by Type (2021–2032)
Figure 55. Global Sales Market Share of Anti-VEGF Drugs for the Treatment of Wet AMD by Application (2021–2032)
Figure 56. Global Revenue Market Share of Anti-VEGF Drugs for the Treatment of Wet AMD by Application (2021–2032)
Figure 57. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price (US$/Dose) by Application (2021–2032)
Figure 58. Anti-VEGF Drugs for the Treatment of Wet AMD Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit